Shahrani, Shahreedhan and balakrishnan, Preetica mayuri and ravi, Koshni and singh, sandeep and chee, sher wye and zulkeflie, saiful hasyim and ng, ying zhuang and lee, wai kin and AK, Mohamed amin and Sooi, Choong Yeong and CK, vikneshwaran and Nik Muhamad Affendi, Nik Arsyad and skantha, ruben and Limun, Mohd Fairul and Wan ibrahim, Nik Razima and Mohamed Talha, Abdul Malik and Chuah, Kee Huat and Stanley, khoo and Rajaram, Ruveena Bhavani and chan, wah keong and Mahadeva, Sanjiv and UNSPECIFIED and UNSPECIFIED and UNSPECIFIED
(2022)
Frequency of significant steatosis in various chronic liver diseases: an evaluation with Transient Elastography (TE).
In: GUT 2022, 19 - 21 August 2022, kuala Lumpur convention centre.
(Unpublished)
Abstract
INTRODUCTION: TE was developed as a non-invasive method to assess liver fibrosis and steatosis using shear wave velocity. Many studies have proven its’ effectiveness as a method for evaluating liver fibrosis and steatosis.1-2
OBJECTIVE: To determine the prevalence and aetiology of steatosis in our local population.
METHOD: This study was conducted as a retrospective review on all patients who had TE performed at UMMC from 1 January
2013 to 31 December 2021. Their demographics, clinical characteristics and TE findings were charted.
RESULTS: A total of 3066 patients were included. 51.7% were males and 48.3% were females. The median CAP value was 271 dB/m. The median E value was 6.5kPa. 61.2% of patients had steatosis, with a staggering number of of these patients having significant steatosis (51.8%). 6.3% of patients had S2 steatosis whereas 45.5% of patients had severe (S3) steatosis. Interestingly, in those with S2 steatosis, 34.7% had chronic hepatitis B (CHB), 31.5% had non-alcoholic fatty liver disease (NAFLD), 5.2% with chronic hepatitis C (CHC) and 1% had alcoholic liver disease (ALD). In the S3 steatosis group, 66.7% had NAFLD, followed by ALD (36.6%), CHB (30.1%) and CHC (27.7%).
221
DISCUSSION: It is important to highlight that a large proportion of our patients has significant steatosis. This is likely in keeping with the global rise of obesity and sedentary lifestyle.3 NAFLD is a 4-decades old nomenclature that does not appropriately address the heterogenous pathogenicity of fatty liver disease. Our study reflects this heterogeneity, as it shows that steatosis often co-exists with other diverse aetiologies.
CONCLUSION: Whilst NAFLD clearly has the greatest frequency of severe steatosis, it is also present in other aetiologies. These findings support the new terminology of metabolic associated fatty liver disease (MAFLD), which reflects the fact that NAFLD commonly co-exists with other aetiologies.
Actions (login required)
 |
View Item |
Download Statistics
Download Statistics